Michael Gelband’s Kymera Therapeutics KYMR Stock Holding History

Michael Gelband’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-28,318	Closed	-$2.36M	–	1836
2026 Q1	$2.36M	Buy	+28,318	New	+$2.24M	0.02%	724
2025 Q3	–	Sell	-100,997	Closed	-$4.41M	–	1791
2025 Q2	$4.41M	Buy	100,997 +71,496	+242%	+$2.46M	0.04%	461
2025 Q1	$807K	Buy	29,501 +15,375	+109%	+$560K	0.01%	973
2024 Q4	$568K	Buy	+14,126	New	+$638K	﹤0.01%	1121
2023 Q4	–	Sell	-11,217	Closed	-$156K	–	1778
2023 Q3	$156K	Sell	11,217 -174,308	-94%	-$3.5M	﹤0.01%	1560
2023 Q2	$4.26M	Buy	+185,525	New	+$5.32M	0.03%	510
2022 Q4	–	Sell	-21,552	Closed	-$469K	–	1899
2022 Q3	$469K	Buy	+21,552	New	+$568K	0.01%	1389
2020 Q4	–	Sell	-15,969	Closed	-$516K	–	2182
2020 Q3	$516K	Buy	+15,969	New	+$487K	0.01%	995

Other funds holding KYMR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Michael Gelband's KYMR Position: Q2 2026 in Review

Michael Gelband sold out of Kymera Therapeutics (KYMR) in Q2 2026, closing a stake of 28,318 shares — an estimated $2.36M sold.

Michael Gelband first reported a position in KYMR in Q3 2020 and held it in 8 quarters. The position peaked at $4.41M in Q2 2025. 273 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

Michael Gelband reported no remaining Kymera Therapeutics position as of Q2 2026 after selling out during the quarter.
Michael Gelband sold 28,318 Kymera Therapeutics shares in Q2 2026, an estimated $2.36M.
Michael Gelband first reported a position in Kymera Therapeutics in Q3 2020 and held it in 8 quarters.
Michael Gelband's Kymera Therapeutics position peaked at $4.41M in Q2 2025.
273 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.